Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record.

How Drugs are Developed and Approved by the FDA: Current Process and Future Directions

Ciociola, Arthur A, Cohen, Lawrence B, Kulkarni, Prasad, Kefalas, Costas, Buchman, Alan, Burke, Carol, Cain, Tedd, Connor, Jason, Ehrenpreis, Eli D, Fang, John, Fass, Ronnie, Karlstadt, Robyn, Pambianco, Dan, Phillips, Joseph, Pochapin, Mark, Pockros, Paul, Schoenfeld, Philip, Vuppalanchi, Raj·2014·American Journal of Gastroenterology

Abstract

OBJECTIVES: This article provides an overview of FDA's regulatory processes for drug development and approval, and the estimated costs associated with the development of a drug, and also examines the issues and challenges facing the FDA in the near future. METHODS: A literature search was performed using MEDLINE to summarize the current FDA drug approval processes and future directions. MEDLINE was further utilized to search for all cost analysis studies performed to evaluate the pharmaceutical industry R&D productivity and drug development cost estimates. RESULTS: While the drug approval process remains at high risk and spans over multiple years, the FDA drug review and approval process has improved, with the median approval time for new molecular drugs been reduced from 19 months to 10 months. The overall cost to development of a drug remains quite high and has been estimated to range from $868M to $1,241M USD. Several new laws have been enacted, including the FDA Safety and Innovation Act (FDASIA) of 2013, which is designed to improve the drug approval process and enhance access to new medicines. CONCLUSIONS: The FDA's improved processes for drug approval and post-market surveillance have achieved the goal of providing patients with timely access to effective drugs while minimizing the risk of drug-related harm. The FDA drug approval process is not without controversy, as a number of well-known gastroenterology drugs have been withdrawn from the US market over the past few years. With the approval of the new FDASIA law, the FDA will continue to improve their processes and, working together with the ACG through the FDA-Related Matters Committee, continue to develop safe and effective drugs for our patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ajg.2013.407

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 162

Metadata

Authors
Ciociola, A. A., Cohen, L. B., Kulkarni, P., Kefalas, C., Buchman, A., Burke, C., Cain, T., Connor, J., Ehrenpreis, E. D., Fang, J., Fass, R., Karlstadt, R., Pambianco, D., Phillips, J., Pochapin, M., Pockros, P., Schoenfeld, P., & Vuppalanchi, R.
Venue
American Journal of Gastroenterology
Published
2014-05
Volume
109
Issue
5
Pages
620-623
ISSN
0002-9270 (ISSN-L)
OpenAlex
W1971008225
Cited by
162
References
0
FWCI
31.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: How Drugs are Developed and Approved by the FDA: Current Process and Future Directions. https://app.cochat.ai/papers/10.1038/ajg.2013.407
The paper
Ciociola, A. A., Cohen, L. B., Kulkarni, P., Kefalas, C., Buchman, A., Burke, C., Cain, T., Connor, J., Ehrenpreis, E. D., Fang, J., Fass, R., Karlstadt, R., Pambianco, D., Phillips, J., Pochapin, M., Pockros, P., Schoenfeld, P., & Vuppalanchi, R. (2014). How Drugs are Developed and Approved by the FDA: Current Process and Future Directions. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2013.407

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.